Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial by Blay, Jean-Yves, Prof, Chevret, Sylvie, Prof, Le Cesne, Axel, Prof, Brahmi, Mehdi, MD, Penel, Nicolas, Prof, Cousin, Sophie, MD, Bertucci, Francois, Prof, Bompas, Emmanuelle, MD, Ryckewaert, Thomas, MD, Soibinet, Pauline, MD, Boudou-Rouquette, Pascaline, MD, Saada Bouzid, Esma, MD, Soulie, Patrick, MD, Valentin, Thibaud, MD, Lotz, Jean-Pierre, Prof, Tosi, Diego, MD, Neviere, Zoé, MD, Cancel, Mathilde, MD, Ray-Coquard, Isabelle, Prof, Gambotti, Laetitia, MD, Legrand, Frédéric, PhD, Lamrani-Ghaouti, Assia, PhD, Simon, Clotilde, PhD, Even, Caroline, MD, Massard, Christophe, Prof

Get full text

Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, r... by Blay, Jean-Yves, Prof, Devin, Quentin, MSc, Duffaud, Florence, Prof, Toulmonde, Maud, MD, Firmin, Nelly, MD, Collard, Olivier, MD, Bompas, Emmanuelle, MD, Verret, Benjamin, MD, Ray-Coquard, Isabelle, Prof, Salas, Sebastien, Prof, Henon, Clemence, MD, Honoré, Charles, MD, Brahmi, Mehdi, MD, Dufresne, Armelle, MD, Pracht, Marc, MD, Hervieu, Alice, MD, Penel, Nicolas, Prof, Bertucci, Francois, Prof, Rios, Maria, MD, Saada-Bouzid, Esma, MD, Soibinet, Pauline, MD, Perol, David, MD, Chabaud, Sylvie, PhD, Italiano, Antoine, Prof, Cesne, Axel Le, MD

Get full text